# NCT02952586 (NCT02952586)

> Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02952586
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Pfizer
- Conditions: Squamous Cell Carcinoma of the Head and Neck
- Interventions: Avelumab; Chemoradiation
- Enrollment: 697
- Primary outcome: Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as Assessed by Investigator

## Commentary we found

- Podcasts: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02952586